Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30 avr. 2024 01h00 HE
|
Ultimovacs ASA
Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 10h15 HE
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer...
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
18 avr. 2024 08h42 HE
|
Ultimovacs ASA
Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one...
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
16 avr. 2024 16h10 HE
|
Ultimovacs ASA
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to...
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
15 avr. 2024 01h00 HE
|
Ultimovacs ASA
Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based...
Ultimovacs – Invitation to Business Update on April 17, 2024
09 avr. 2024 14h00 HE
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing...
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
04 avr. 2024 01h00 HE
|
Ultimovacs ASA
Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101...
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
25 mars 2024 02h00 HE
|
Ultimovacs ASA
Oslo, March 25, 2024, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") at 14:00 CET on April 18, 2024. The General Meeting will be held...
Ultimovacs ASA: Mandatory notification of trade by primary insider
22 mars 2024 08h27 HE
|
Ultimovacs ASA
Oslo, March 22, 2024, Board member Henrik Schüssler and primary insider in Ultimovacs ASA, has today through FireH AS bought 50,000 shares in the company at a price of NOK 6.398 per share. Following...
Ultimovacs ASA: Annual Report 2023
21 mars 2024 02h00 HE
|
Ultimovacs ASA
Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs...